No profile data available.
Ascendis Pharma A/S (ASND) is a healthcare company in the hormonal regulation treatment drugs industry, based in Hellerup, Denmark, with about 1,189 full-time employees.
It reported revenue of 720.13 million EUR for fiscal year 2025, up 98.0% from fiscal year 2024, and net income of -228.03 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 339.29 million EUR, up 114.7% from a year before. United States was its largest region in fiscal year 2025, with 76% of revenue. Its market capitalization was $15.08 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Ascendis Pharma A/S reported 720.13 million EUR in revenue for fiscal year 2025, up 98.0% from 363.64 million EUR in fiscal year 2024. In Q2 2026 revenue was 339.29 million EUR.
United States: 76% of revenue by region in fiscal year 2025, followed by Europe (15%).
$15.08 billion as of October 9, 2026.